Draft scoping review: melanocortin receptor agonists — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. Studies not published in English were excluded without assessment — arising from DRAFT-MELANOCORTIN/009. Language restriction is removed from the protocol for the series, the records previously excluded on that ground are listed with their screening outcome, and the residual limitation is stated in the abstract of this review.
2. Patient-reported outcomes are collected by the trials and not reported by the review — arising from DRAFT-MELANOCORTIN/010. Patient-reported outcomes measured by any contributing trial are now reported narratively by instrument, with the instrument named and its minimum important difference stated where one is published, and the absence of a pooled estimate explained.
3. The choice of effect measure is not justified and changes the appearance of the result — arising from DRAFT-MELANOCORTIN/001. Every outcome now reports the relative effect and, where an assumed baseline risk can be stated and sourced, the corresponding absolute effect, with the baseline risk and its source given in the same row.
4. An indirect comparison is presented without an assessment of transitivity — arising from DRAFT-MELANOCORTIN/008. Transitivity is now assessed against a stated list of effect modifiers and reported before any indirect estimate, and where the assessment fails the contrast is reported as unestimable with the reason rather than estimated with a caveat.
5. References should carry a persistent identifier for every cited source — arising from DRAFT-MELANOCORTIN/002. Every reference without a persistent identifier now carries an explicit statement that the identifier is not held by the Institute, so that its absence is a recorded fact rather than an apparent oversight.
6. Analytical surveys are treated as evidence about suppliers when they establish only what was in a… — arising from DRAFT-MELANOCORTIN/006. Provenance is now assessed for every included survey and reported as a study characteristic, surveys without establishable provenance are reported separately rather than pooled with those that have it, and no supplier-level inference is drawn from a…
7. The conclusion is stated more strongly than the certainty rating supports — arising from DRAFT-MELANOCORTIN/004. Conclusion wording is now drawn from a fixed set of formulations tied to the certainty rating, so that a low certainty rating produces a statement that the evidence may suggest an effect and that the estimate is likely to change with further research.
8. The search date is not on the face of the document — arising from DRAFT-MELANOCORTIN/011. The search date is now printed adjacent to every certainty rating and is carried in the document metadata, so that the interval between the search and the reading is visible without reference to the methods section.
9. Statistical heterogeneity is treated as though it measured clinical heterogeneity — arising from DRAFT-MELANOCORTIN/003. The decision to pool is now justified in prose against the population, intervention, comparator and outcome before any statistic is presented, and the heterogeneity statistic is reported with its confidence interval and a note of the number of contributing…

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.